First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial

Purpose To outline the dose rationale for the first in-human intrathecal delivery of bevacizumab for LMS of GBM. Methods A 19-year-old female patient presented to Lenox Hill Hospital following thalamic GBM recurrence. She subsequently underwent two infusions of intra-arterial BEV (NCT01269853) and e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2023-08, Vol.164 (1), p.231-237
Hauptverfasser:	Holdaway, Matthew, Ablyazova, Faina, Huda, Shayan, D’Amico, Randy S., Wong, Tamika, Shani, Dana, Ben-Shalom, Netanel, Boockvar, John A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bevacizumab Brain cancer Cancer therapies Chemotherapy Drug dosages Glioblastoma Hospitals Magnetic resonance imaging Medical prognosis Medicine Medicine & Public Health Meninges Metastasis Monoclonal antibodies Neurology Oncology Patients Radiation Targeted cancer therapy Thalamus Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!